• Palisade Bio set a Phase 2 ulcerative colitis trial for PALI-2108 to start in Q3 2026, with an IND filing expected in Q2 2026.
• Results have already been presented from Phase 1a/1b studies, including a Phase 1b fibrostenotic Crohn’s disease cohort, supporting advancement into mid-stage development.
• Program showed favorable safety and tolerability, with evidence of drug activity in intestinal tissue and early signals of clinical benefit in Crohn’s disease, without reporting technical performance figures.
• Phase 2 ulcerative colitis primary efficacy results are expected in 2H 2027; Phase 2 Crohn’s disease trial start is targeted for Q1 2027 with a readout expected early 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palisade Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001357459-26-000011), on May 12, 2026, and is solely responsible for the information contained therein.